On this board there have been many comments about the superbugs and CTIX in the last several days. In the nicest way possible I simply wanted to point out that Brilacidin - so far as I know- would not kill those bacteria. This of course does not apply to what CTIX might have up its sleeve at Fox Chase etc- but these drugs are a long way out. Is that leading, or loaded?
i see that Klebsiella is also mentioned in a Polymedix article, in addition to E Coli. This in and of itself is sensational. Daptomycin and Vancomycin would have NO gm - activity for example.
How is this relevant? let's take a common scenario- an IV drug user shows up in the Emergency Dept with an abscess. Usu they have a gm + source, but IV drug users can have unusual gm - too. One drug to get both? That is excellent, extraordinary.
You are free to doubt my motives, which are actually quite simple: at what point is CTIX ok to buy into? Even if Brilacidin is great, disappointing trial results with Kevetrin would have to lower share price. At the point when Kevetrin proves its worth in trials, or maybe even with good results in the next cohort or two, all those who have locked in shares will be big winners, and I will be struggling to get shares at a much higher price.
My other motive in watching this company is simple: these drugs would really benefit a lot of people. Since when does one small company have a potentially revolutionary antibiotic platform and a revolutionary chemo agent? From a clinical standpoint, a drug like Brilacidin would make the job of every physician easier(No I am not a pretend MD. I actually went to medical school and have practiced medicine for more than 20 years). And as I said prev, my sister in law has metastatic pancreatic CA, and Kevetrin might save some of those pts in the future.
